Mobile

A Phase 1, Randomized, Open-label, Single-Dose, Crossover, Relative Bioavailability, and Food-Effect Study of a Pediatric Chewable Tablet Formulation Relative to a 375-mg Core Tablet Formulation of Te...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021156-26

A Phase 1, Randomized, Open-label, Single-Dose, Crossover, Relative Bioavailability, and Food-Effect Study of a Pediatric Chewable Tablet Formulation Relative to a 375-mg Core Tablet Formulation of Telaprevir in Healthy Adult Subjects

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- To determine the bioavailability of telaprevir administered as a pediatric chewable tablet formulation relative to a 375-mg core tablet formulation in the fed state - To evaluate the effect of food on the pharmacokinetics of telaprevir administered as a pediatric chewable tablet formulation

Critère d'inclusion

  • chronic hepatitis c virus genotype 1 infection

Liens